Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,545,740
  • Shares Outstanding, K 1,092,190
  • Annual Sales, $ 16,887 M
  • Annual Income, $ -998,000 K
  • 60-Month Beta 1.48
  • Price/Sales 0.57
  • Price/Cash Flow 2.25
  • Price/Book 0.65
Trade TEVA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.56
  • Number of Estimates 4
  • High Estimate 0.58
  • Low Estimate 0.55
  • Prior Year 0.56
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.46 +3.07%
on 10/30/20
10.09 -13.58%
on 10/09/20
-0.29 (-3.22%)
since 09/30/20
3-Month
8.46 +3.07%
on 10/30/20
12.81 -31.93%
on 08/06/20
-2.84 (-24.57%)
since 07/30/20
52-Week
6.25 +39.52%
on 03/18/20
13.76 -36.63%
on 02/12/20
+0.53 (+6.47%)
since 10/30/19

Most Recent Stories

More News
ROSEN, A LEADING LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - TEVA

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between and , inclusive (the "Class...

TEVA : 8.72 (-0.23%)
US Biosimilars Market: Industry Share, Size, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast to 2025

Biosimilars Market is valued at USD 7.49 Billion in 2018 and expected to reach USD 34.39 Billion by 2025 with the CAGR of 24.32% over the forecast period.

ACT : 27.04 (-0.84%)
AMGN : 216.94 (-0.40%)
PFE : 35.48 (+0.57%)
STDAF : 110.4200 (unch)
TEVA : 8.72 (-0.23%)
Global Non-Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 Countries) - Analysis and Forecast, 2020-2030

, /PRNewswire/ -- Read the full report: Market Segmentation• By Application: Infectious Diseases, Neurology, Cardiovascular, Lifestyle and Endocrinology, Gastroenterology, Other Applications• By...

ABT : 105.11 (+0.10%)
A : 102.09 (+0.07%)
GILD : 58.15 (-0.65%)
GSK : 33.42 (-1.59%)
ILMN : 292.70 (-7.05%)
NVTA : 39.21 (-10.40%)
LH : 199.77 (+0.13%)
OPK : 3.52 (-16.19%)
TEVA : 8.72 (-0.23%)
Smart Inhalers Markets, 2025 - Inhibiting Factors and Impact of COVID-19 Shaping the Global Market

, /PRNewswire/ -- The report has been added to offering.

AZN : 50.16 (-1.78%)
GSK : 33.42 (-1.59%)
NVS : 78.08 (+0.01%)
OPK : 3.52 (-16.19%)
RMD : 191.94 (+6.92%)
TEVA : 8.72 (-0.23%)
VEGPF : 1.3156 (-3.97%)
Teva Shareholder Notice

New York, New York--(Newsfile Corp. - October 28, 2020) -   and would like to discuss your legal rights, click here or call Faruqi & Faruqi partner at or .

TEVA : 8.72 (-0.23%)
Rosen, Top Ranked Investor Counsel, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - TEVA

New York, New York--(Newsfile Corp. - October 28, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE:...

TEVA : 8.72 (-0.23%)
Teva Shareholder Alert

New York, New York--(Newsfile Corp. - October 27, 2020) -  and would like to discuss your legal rights, click here or call Faruqi & Faruqi partner at or .

TEVA : 8.72 (-0.23%)
Influenza Medication Market to Hit $993.7 Million with 2.2% CAGR by 2026; Large Unmet Needs of Patient Population to Boost Market Growth in Latin America: Fortune Business Insights(TM)

The global influenza medication market size is projected to reach USD 993.7 million by 2026, exhibiting a CAGR of 2.2% during the forecast period. Increasing global burden of influenza will be one of the...

BCRX : 3.82 (+2.41%)
GSK : 33.42 (-1.59%)
SGIOF : 46.8500 (+0.09%)
TEVA : 8.72 (-0.23%)
Teva Deadline Alert

New York, New York--(Newsfile Corp. - October 26, 2020) -  and would like to discuss your legal rights, click here or call Faruqi & Faruqi partner at or .

TEVA : 8.72 (-0.23%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teva Pharmaceuticals Industries Limited of Class Action Lawsuit and Upcoming Deadline - TEVA

Pomerantz LLP announces that a class action lawsuit has been filed against Teva Pharmaceuticals Industries Limited ("Teva" or the "Company") (NYSE: TEVA) and certain of its officers. The class action,...

TEVA : 8.72 (-0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

2nd Resistance Point 8.89
1st Resistance Point 8.81
Last Price 8.72
1st Support Level 8.55
2nd Support Level 8.37

See More

52-Week High 13.76
Fibonacci 61.8% 10.89
Fibonacci 50% 10.01
Fibonacci 38.2% 9.12
Last Price 8.72
52-Week Low 6.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar